Try our mobile app

Switch to company model in classical logic    *

General information

Country: BERMUDA

Sector: Biotechnology

Kiniksa Pharmaceuticals, Ltd. doing business as Kiniksa Pharmaceuticals Corp. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals serves patients worldwide.
Website: kiniksa.com



Growth: Good revenue growth rate 48.2%, there is slowdown compared to average historical growth rates 104.5%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +55.7%. On average the margin is improving steadily. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.58 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 1.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 154.1% higher than minimum and 30.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 8.6x by EV / Sales multiple , the company can be >100% undervalued

Insiders: For the last 3 months insiders sold company shares on $2.4 mln (-0.151% of cap.)

Key Financials (Download financials)

Ticker: KNSA
Share price, USD:  (0.0%)19.31
year average price 21.77  


year start price 17.44 2024-04-15

min close price 16.88 2024-04-18

max close price 27.65 2024-10-29

current price 19.31 2025-04-14
Common stocks: 71 726 685

Dividend Yield:  0.0%
FCF Yield LTM: 1.5%
EV / LTM EBITDA: 4.9x
EV / EBITDA annualized: 1.1x
Last revenue growth (y/y):  +48.2%
Last growth of EBITDA (y/y):  > +200.0%
Historical revenue growth:  +104.5%
Historical growth of EBITDA:  +32.8%
EV / Sales: 2.7x
Margin (EBITDA LTM / Revenue): 55.7%
Fundamental value created in LTM:
Market Cap ($m): 1 385
Net Debt ($m): -234
EV (Enterprise Value): 1 151
Price to Book: 3.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-04-08zacks.com

Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?

2025-04-04zacks.com

Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know

2025-03-04zacks.com

Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?

2025-02-25zacks.com

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates

2025-02-20globenewswire.com

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

2024-10-29seekingalpha.com

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call Transcript

2024-10-29zacks.com

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates

2024-10-22globenewswire.com

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

2024-10-11zacks.com

What Makes Kiniksa Pharmaceuticals (KNSA) a Good Fit for 'Trend Investing'

2024-10-09zacks.com

Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-10-29 2024-07-25 2024-04-25 2024-02-28 2023-11-02 2023-08-01 2023-05-04 2023-03-02 2022-11-03
acceptedDate 2024-10-29 16:14:07 2024-07-25 16:10:34 2024-04-25 16:16:04 2024-02-28 16:16:09 2023-11-02 16:15:43 2023-08-01 16:15:29 2023-05-04 16:15:43 2023-03-02 16:16:15 2022-11-03 16:16:28
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 112M 109M 80M 83M 67M 71M 48M 62M 99M
costOfRevenue 49M 42M 32M 27M 26M 22M 7M 14M 12M
grossProfit 63M 66M 48M 57M 41M 50M 41M 48M 88M
grossProfitRatio 0.56 0.609 0.605 0.679 0.606 0.697 0.854 0.77 0.883
researchAndDevelopmentExpenses 26M 24M 26M 20M 17M 24M 15M 14M 16M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 46M 42M 39M 37M 34M 29M 29M 27M 25M
otherExpenses 0 2M 2M 2M 2M 2M 8M 0 0
operatingExpenses 72M 66M 65M 57M 52M 53M 53M 42M 41M
costAndExpenses 122M 109M 96M 83M 78M 75M 60M 56M 53M
interestIncome 0 0 0 2M 2M 2M 0 794 000 322 000
interestExpense 0 0 0 2M 0 0 -2M 794 000 322 000
depreciationAndAmortization 399 000 430 000 466 000 236 000 603 000 602 000 596 000 0 0
ebitda -10M 313 000 -16M 317 000 -11M -3M -11M 6M 46M
ebitdaratio -0.086 0.003 -0.201 0.004 -0.163 -0.044 -0.232 0.098 0.468
operatingIncome -10M -117 000 -17M 81 000 -11M -3M -11M 6M 46M
operatingIncomeRatio -0.086 -0.001 -0.207 0.001 -0.163 -0.044 -0.232 0.098 0.468
totalOtherIncomeExpensesNet 2M 2M 2M 2M 2M 2M 2M 794 000 322 000
incomeBeforeTax -7M 2M -14M 2M -8M -1M -9M 7M 47M
incomeBeforeTaxRatio -0.064 0.021 -0.179 0.029 -0.127 -0.017 -0.194 0.111 0.471
incomeTaxExpense 5M 6M 3M -23M 5M -16M 3M 2M -177M
netIncome -13M -4M -18M 25M -14M 15M -12M 4M 224M
netIncomeRatio -0.113 -0.036 -0.222 0.303 -0.207 0.209 -0.254 0.072 2.26
eps -0.18 -0.055 -0.25 0.36 -0.2 0.21 -0.18 0.06 3.23
epsdiluted -0.18 -0.055 -0.25 0.35 -0.2 0.21 -0.18 0.06 3.18
weightedAverageShsOut 72M 71M 71M 70M 70M 72M 70M 70M 69M
weightedAverageShsOutDil 72M 71M 71M 73M 70M 72M 70M 71M 71M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-10-29 2024-07-25 2024-04-25 2024-02-28 2023-11-02 2023-08-01 2023-05-04 2023-03-02 2022-11-03
acceptedDate 2024-10-29 16:14:07 2024-07-25 16:10:34 2024-04-25 16:16:04 2024-02-28 16:16:09 2023-11-02 16:15:43 2023-08-01 16:15:29 2023-05-04 16:15:43 2023-03-02 16:16:15 2022-11-03 16:16:28
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 97M 99M 141M 108M 118M 113M 81M 123M 176M
shortTermInvestments 126M 119M 72M 98M 83M 72M 107M 68M 25M
cashAndShortTermInvestments 224M 219M 214M 206M 201M 185M 187M 191M 201M
netReceivables 25M 20M 16M 21M 3M 25M 7M 20M 11M
inventory 29M 35M 27M 31M 26M 24M 23M 22M 15M
otherCurrentAssets 34M 27M 14M 18M 26M 12M 151M 11M 15M
totalCurrentAssets 311M 301M 271M 276M 256M 185M 232M 243M 242M
propertyPlantEquipmentNet 12M 12M 13M 13M 14M 14M 1M 7M 8M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 17M 17M 17M 17M 18M 18M 18M 18M 19M
goodwillAndIntangibleAssets 17M 17M 17M 17M 18M 18M 18M 18M 19M
longTermInvestments 0 -1 -245M -1 0 0 0 0 0
taxAssets 208M 204M 215M 219M 194M 204M 184M 185M 186M
otherNonCurrentAssets 8M 8M 249M 827 000 2M 2M 8M 6M 6M
totalNonCurrentAssets 244M 241M 249M 250M 227M 238M 211M 217M 218M
otherAssets 0 1 0 1 0 61M 0 0 0
totalAssets 555M 542M 520M 526M 483M 484M 443M 460M 460M
accountPayables 8M 7M 6M 8M 1M 648 000 1M 8M 1M
shortTermDebt 4M 4M 2M 2M 2M 2M 3M 3M 3M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 12 000 156 000 307 000 3M 5M 6M 12M 12M
otherCurrentLiabilities 84M 73M 56M 53M 48M 40M 25M 24M 40M
totalCurrentLiabilities 96M 84M 64M 64M 53M 47M 37M 47M 56M
longTermDebt 9M 9M 10M 10M 11M 11M 2M 3M 3M
deferredRevenueNonCurrent 12M 12M 12M 12M 12M 12M 12M 12M 14M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 2M 2M 2M 2M 2M 2M 2M 2M 3M
totalNonCurrentLiabilities 22M 23M 24M 24M 24M 25M 16M 16M 19M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 11M 11M 10M 10M 13M 14M 6M 6M 7M
totalLiabilities 118M 107M 88M 87M 78M 73M 53M 64M 76M
preferredStock 0 110 000 0 0 0 0 0 0 0
commonStock 20 000 20 000 20 000 20 000 15 000 14 000 14 000 19 000 19 000
retainedEarnings -512M -500M -496M -478M -503M -489M -504M -492M -496M
accumulatedOtherComprehensiveIncomeLoss -41 000 -130 000 -53 000 6000 -1000 13 000 55 000 44 000 -70 000
othertotalStockholdersEquity 949M 935M 928M 917M -14 000 -27 000 -69 000 -63 000 51 000
totalStockholdersEquity 437M 435M 432M 439M -503M -489M -504M -492M -496M
totalEquity 437M 435M 432M 439M -503M -489M -504M -492M -496M
totalLiabilitiesAndStockholdersEquity 555M 542M 520M 526M -425M -417M -452M -429M -421M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 555M 542M 520M 526M -425M -417M -452M -429M -421M
totalInvestments 126M 119M 72M 98M 83M 72M 107M 68M 25M
totalDebt 11M 11M 12M 12M 13M 14M 6M 6M 7M
netDebt -87M -88M -129M -96M -105M -99M -75M -117M -169M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-10-29 2024-07-25 2024-04-25 2024-02-28 2023-11-02 2023-08-01 2023-05-04 2023-03-02 2022-11-03
acceptedDate 2024-10-29 16:14:07 2024-07-25 16:10:34 2024-04-25 16:16:04 2024-02-28 16:16:09 2023-11-02 16:15:43 2023-08-01 16:15:29 2023-05-04 16:15:43 2023-03-02 16:16:15 2022-11-03 16:16:28
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -13M -4M -18M 25M -14M 15M -12M 4M 224M
depreciationAndAmortization 399 000 430 000 466 000 236 000 603 000 602 000 596 000 602 000 493 000
deferredIncomeTax -4M 11M 4M -26M 10M -19M 1M 348 000 0
stockBasedCompensation 8M 7M 7M 8M 7M 6M 6M 6M 6M
changeInWorkingCapital 6M -10M 9M -4M 11M -6M 260 000 -24M 17M
accountsReceivables -4M -4M 5M -18M 22M -17M 5M -2M -3M
inventory 6M -8M 4M -6M -2M -533 000 -2M -7M 5M
accountsPayables 911 000 2M -3M 7M 364 000 -743 000 -7M 6M -1M
otherWorkingCapital 3M 397 000 2M 13M -9M 13M 3M -22M 16M
otherNonCashItems 267 000 19M 3M 749 000 2M -383 000 -45 000 595 000 -185M
netCashProvidedByOperatingActivities -2M 5M 4M 4M 17M -4M -4M -12M 62M
investmentsInPropertyPlantAndEquipment 0 0 -84 000 -56 000 -16 000 -34 000 -24 000 32 000 -22 000
acquisitionsNet -25 000 25 000 0 15M 12M -36M 0 0 0
purchasesOfInvestments -54M -89M -36M -61M -53M -38M -53M -63M -17M
salesMaturitiesOfInvestments 48M 42M 62M 46M 41M 74M 15M 20M 36M
otherInvestingActivites 25 000 -47M 26M -15M -12M 36M 0 10000 -10000
netCashUsedForInvestingActivites -6M -47M 26M -15M -12M 36M -38M -43M 19M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 0 0 4M 695 000 552 000 158 000 0 1M 0
commonStockRepurchased -3M -1M -381 000 -262 000 -1M -419 000 -420 000 -100 000 -208 000
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 9M 1M -381 000 262 000 1M 419 000 510 000 0 569 000
netCashUsedProvidedByFinancingActivities 7M -178 000 4M 695 000 552 000 158 000 90 000 1M 361 000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0
netChangeInCash -2M -42M 33M -10M 5M 32M -42M -53M 81M
cashAtEndOfPeriod 97M 99M 141M 108M 118M 113M 81M 123M 176M
cashAtBeginningOfPeriod 99M 141M 108M 118M 113M 81M 123M 176M 94M
operatingCashFlow -2M 5M 4M 4M 17M -4M -4M -12M 62M
capitalExpenditure 0 0 -84 000 -56 000 -16 000 -34 000 -24 000 32 000 -22 000
freeCashFlow -2M 5M 4M 4M 17M -4M -4M -12M 62M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-29 ET (fiscal 2024 q3)
2024 q2
2024-07-23 ET (fiscal 2024 q2)
2024 q1
2024-04-23 ET (fiscal 2024 q1)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-10-31 ET (fiscal 2023 q3)
2023 q2
2023-07-25 ET (fiscal 2023 q2)
2023 q1
2023-05-06 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-05 ET (fiscal 2022 q2)
2022 q1
2022-05-07 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-29 11:30 ET
Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution
2024-10-28 12:00 ET
Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
2024-10-22 20:01 ET
Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024
2024-10-01 12:00 ET
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
2024-08-28 20:01 ET
Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference
2024-07-23 11:30 ET
Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
2024-07-16 20:01 ET
Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024
2024-07-09 12:00 ET
Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease
2024-06-24 12:00 ET
Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis
2024-06-17 12:30 ET
Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative
2024-06-04 20:01 ET
Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
2024-06-03 11:00 ET
Sector Spotlight: Orphan Drug Developers With Significant Upside
2024-05-07 20:01 ET
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
2024-04-23 11:30 ET
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
2024-04-16 20:01 ET
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
2024-04-02 11:30 ET
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
2024-02-28 12:30 ET
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
2024-02-21 21:01 ET
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
2024-01-04 12:30 ET
Kiniksa Pharmaceuticals Provides Corporate Update
2024-01-02 21:01 ET
Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-10-31 11:30 ET
Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution
2023-10-24 20:01 ET
Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023
2023-07-25 11:30 ET
Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
2023-07-17 12:00 ET
Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023
2023-06-06 20:01 ET
Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-02 11:30 ET
Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution
2023-05-01 20:01 ET
Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023
2023-02-28 13:00 ET
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution
2023-02-27 21:01 ET
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023
2023-01-09 13:00 ET
Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update
2023-01-03 21:01 ET
Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
2022-11-30 21:01 ET
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference
2022-11-23 21:01 ET
Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference
2022-11-01 12:00 ET
Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
2022-10-31 20:01 ET
Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022
2022-09-12 12:30 ET
Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab
2022-08-03 20:01 ET
Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference
2022-08-03 11:30 ET
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
2022-08-03 11:29 ET
Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab
2022-08-02 20:01 ET
Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
2022-05-03 12:00 ET
Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
2022-05-02 20:01 ET
Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022
2022-02-22 13:00 ET
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
2022-02-22 12:59 ET
Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration
2022-02-18 21:01 ET
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022
2022-01-10 13:00 ET
Kiniksa Provides Corporate Update and Outlines Anticipated 2022 Milestones
2022-01-03 21:01 ET
Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
2021-12-28 11:59 ET
Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS
2021-11-23 21:01 ET
Kiniksa Pharmaceuticals to Present at Evercore ISI 4th Annual HealthCONx Conference
2021-11-01 12:00 ET
Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution
2021-10-29 20:01 ET
Kiniksa Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 1, 2021
2021-09-21 20:01 ET
Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
2021-08-16 12:00 ET
Kiniksa Announces Launch of ARCALYST Named Patient Program
2021-08-03 12:00 ET
Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
2021-08-02 20:01 ET
Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
2021-07-20 20:01 ET
Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021
2021-06-08 20:01 ET
Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis
2021-06-08 11:30 ET
Kiniksa Outlines Next Steps for the Development of Mavrilimumab
2021-06-01 20:01 ET
Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference
2021-05-04 12:00 ET
Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
2021-05-04 11:59 ET
Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404
2021-04-12 11:30 ET
Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients
2021-04-01 12:00 ET
Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis
2021-03-18 20:30 ET
Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis
2021-03-02 13:00 ET
Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis
2021-02-23 13:00 ET
Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity
2021-01-11 13:00 ET
Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones
2021-01-04 21:19 ET
Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
2020-12-22 13:00 ET
Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation
2020-12-15 13:00 ET
Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis
2020-11-30 13:00 ET
Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404
2020-11-24 13:00 ET
Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference
2020-11-23 13:00 ET
Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis
2020-11-17 13:00 ET
Kiniksa Announces New England Journal of Medicine Publication of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020
2020-11-16 13:00 ET
Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis
2020-11-09 21:01 ET
Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data
2020-11-05 12:30 ET
Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
2020-10-29 12:00 ET
Kiniksa Announces Phase 2 Clinical Data from Vixarelimab in Prurigo Nodularis to be Presented at European Academy of Dermatology and Venereology Virtual Congress
2020-10-26 12:00 ET
Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020
2020-10-06 12:00 ET
Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis
2020-09-24 20:12 ET
Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th
2020-09-21 12:00 ET
Kiniksa Announces Upcoming Rilonacept Analyst Day
2020-09-15 12:00 ET
Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis
2020-09-09 20:01 ET
Kiniksa Pharmaceuticals to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
2020-08-31 12:00 ET
Kiniksa Presents Data on the Burden of Disease in Patients with Recurrent Pericarditis at the European Society of Cardiology Congress 2020
2020-08-04 12:00 ET
Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference
2020-07-30 11:30 ET
Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
2020-07-22 01:55 ET
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering
2020-07-20 20:07 ET
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering
2020-07-16 11:30 ET
Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis
2020-06-29 11:15 ET
Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
2020-06-17 12:00 ET
Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19
2020-06-10 12:00 ET
Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts
2020-06-08 12:00 ET
Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial
2020-06-04 12:00 ET
Kiniksa Pharmaceuticals to Present at 41st Annual Goldman Sachs Global Healthcare Conference
2020-05-29 12:30 ET
Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020
2020-05-18 20:01 ET
Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2020-05-14 03:12 ET
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering
2020-05-13 21:12 ET
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering
2020-05-11 11:30 ET
Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus
2020-04-28 11:30 ET
Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity
2020-04-22 12:00 ET
Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint
2020-03-31 12:14 ET
Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation
2020-03-30 11:30 ET
Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session
2020-02-26 12:30 ET
Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity
2020-01-13 13:00 ET
Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts
2019-12-11 13:30 ET
Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
2019-12-10 13:00 ET
Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference
2019-11-20 21:01 ET
Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference
2019-11-20 13:00 ET
Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis
2019-11-16 17:00 ET
Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019
2019-11-12 21:01 ET
Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting
2019-10-28 20:01 ET
Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
2019-09-19 20:01 ET
Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research

SEC forms

Show financial reports only

SEC form 10
2025-02-25 00:00 ET
Kiniksa Pharmaceuticals reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Kiniksa Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Kiniksa Pharmaceuticals published news for 2024 q4
SEC form 10
2024-10-29 16:14 ET
Kiniksa Pharmaceuticals reported for 2024 q3
SEC form 8
2024-10-29 07:31 ET
Kiniksa Pharmaceuticals published news for 2024 q3
SEC form 8
2024-10-29 07:31 ET
Kiniksa Pharmaceuticals published news for 2024 q3
SEC form 10
2024-10-29 00:00 ET
Kiniksa Pharmaceuticals published news for 2024 q3
SEC form 10
2024-07-25 00:00 ET
Kiniksa Pharmaceuticals published news for 2024 q2
SEC form 8
2024-07-23 00:00 ET
Kiniksa Pharmaceuticals reported for 2024 q2
SEC form 8
2024-07-23 00:00 ET
Kiniksa Pharmaceuticals published news for 2024 q2
SEC form 10
2024-04-25 00:00 ET
Kiniksa Pharmaceuticals published news for 2024 q1
SEC form 8
2024-04-23 07:34 ET
Kiniksa Pharmaceuticals published news for 2024 q1
SEC form 8
2024-04-23 07:34 ET
Kiniksa Pharmaceuticals reported for 2024 q1
SEC form 10
2024-02-28 16:16 ET
Kiniksa Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-28 07:35 ET
Kiniksa Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-28 07:35 ET
Kiniksa Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-04 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-04 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-04 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-02 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q3
SEC form 8
2023-10-31 07:35 ET
Kiniksa Pharmaceuticals reported for 2023 q3
SEC form 10
2023-08-01 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-25 07:40 ET
Kiniksa Pharmaceuticals reported for 2023 q2
SEC form 8
2023-07-25 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-07 17:09 ET
Kiniksa Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-02 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q1
SEC form 6
2023-04-27 16:43 ET
Kiniksa Pharmaceuticals published news for 2023 q1
SEC form 6
2023-03-10 20:51 ET
Kiniksa Pharmaceuticals published news for 2022 q4
SEC form 10
2023-03-02 16:16 ET
Kiniksa Pharmaceuticals reported for 2022 q4
SEC form 10
2023-03-02 00:00 ET
Kiniksa Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-28 08:17 ET
Kiniksa Pharmaceuticals published news for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Kiniksa Pharmaceuticals reported for 2022 q4
SEC form 6
2023-01-09 08:05 ET
Kiniksa Pharmaceuticals published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Kiniksa Pharmaceuticals published news for 2022 q4
SEC form 10
2022-11-03 16:16 ET
Kiniksa Pharmaceuticals reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Kiniksa Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-01 08:06 ET
Kiniksa Pharmaceuticals published news for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Kiniksa Pharmaceuticals reported for 2022 q3
SEC form 10
2022-08-04 16:17 ET
Kiniksa Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Kiniksa Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-03 07:35 ET
Kiniksa Pharmaceuticals published news for 2022 q2
SEC form 6
2022-06-30 16:13 ET
Kiniksa Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-05 16:16 ET
Kiniksa Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Kiniksa Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-03 09:09 ET
Kiniksa Pharmaceuticals published news for 2022 q1
SEC form 8
2022-05-03 00:00 ET
Kiniksa Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-28 16:43 ET
Kiniksa Pharmaceuticals published news for 2022 q1
SEC form 10
2022-02-24 16:16 ET
Kiniksa Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-22 08:06 ET
Kiniksa Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-10 08:56 ET
Kiniksa Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-03 16:39 ET
Kiniksa Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-04 16:51 ET
Kiniksa Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-01 08:06 ET
Kiniksa Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-01 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q3
SEC form 10
2021-08-05 16:31 ET
Kiniksa Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-03 08:09 ET
Kiniksa Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-06 17:08 ET
Kiniksa Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-21 17:37 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-21 17:37 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-12 17:02 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 16:30 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-04 08:07 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-28 16:34 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-28 16:05 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-15 17:32 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 6
2021-03-03 16:29 ET
Kiniksa Pharmaceuticals published news for 2020 q4
SEC form 10
2021-02-25 16:13 ET
Kiniksa Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 08:04 ET
Kiniksa Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-11 08:08 ET
Kiniksa Pharmaceuticals published news for 2020 q4
SEC form 6
2020-12-23 17:03 ET
Kiniksa Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-22 16:02 ET
Kiniksa Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-10 16:22 ET
Kiniksa Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-05 16:28 ET
Kiniksa Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-05 07:33 ET
Kiniksa Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-26 08:04 ET
Kiniksa Pharmaceuticals published news for 2020 q3